BMO Capital Markets Reaffirms Outperform Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

BMO Capital Markets restated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNYFree Report) in a research report report published on Wednesday, Benzinga reports. BMO Capital Markets currently has a $234.00 price target on the biopharmaceutical company’s stock.

A number of other brokerages have also recently issued reports on ALNY. Chardan Capital reduced their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a buy rating for the company in a research note on Friday, February 16th. Citigroup dropped their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a buy rating for the company in a report on Friday, February 16th. Piper Sandler raised their price target on Alnylam Pharmaceuticals from $210.00 to $217.00 and gave the company an overweight rating in a report on Thursday, December 14th. Wells Fargo & Company lowered their price objective on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an equal weight rating on the stock in a research report on Friday, February 16th. Finally, HC Wainwright reiterated a buy rating and set a $395.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. Eight investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $216.12.

Check Out Our Latest Report on ALNY

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $154.39 on Wednesday. The stock has a 50-day simple moving average of $161.00 and a two-hundred day simple moving average of $170.62. The firm has a market capitalization of $19.45 billion, a PE ratio of -43.37 and a beta of 0.39. Alnylam Pharmaceuticals has a 52-week low of $143.52 and a 52-week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to the consensus estimate of $439.38 million. The company’s revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.68) earnings per share. Equities analysts forecast that Alnylam Pharmaceuticals will post -4.61 earnings per share for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Quent Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. KB Financial Partners LLC purchased a new stake in Alnylam Pharmaceuticals during the first quarter worth $35,000. Anchor Investment Management LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $38,000. Robeco Institutional Asset Management B.V. increased its holdings in shares of Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 12,513 shares during the period. Finally, GAMMA Investing LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth $52,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

See Also

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.